FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017834862> ?p ?o ?g. }

• W2017834862 endingPage "1109" @default.
• W2017834862 startingPage "1100" @default.
• W2017834862 abstract "Purpose To identify factors predictive for chronic urinary toxicity secondary to high-dose adaptive three-dimensional conformal radiation. Methods and Materials From 1999 to 2002, 331 consecutive patients with clinical Stage II–III prostate cancer were prospectively treated (median dose, 75.6 Gy). The bladder was contoured, and the bladder wall was defined as the outer 3 mm of the bladder solid volume. Toxicity was quantified according to the National Cancer Institute Common Toxicity Criteria 2.0. Median follow-up was 1.6 years. Results The 3-year rates of Grade ≥2 and Grade 3 chronic urinary toxicity were 17.0% and 3.6%, respectively. Prostate volume, confidence-limited patient-specific planning target volume, bladder wall volume, and acute urinary toxicity were all found to be accurate predictors for chronic urinary toxicity. The volume of bladder wall receiving ≥30 Gy (V30) and ≥82 Gy (V82), along with prostate volume, were all clinically useful predictors of Grade ≥2 and Grade 3 chronic urinary toxicity and chronic urinary retention. Both Grade ≥2 (p = 0.001) and Grade 3 (p = 0.03) acute urinary toxicity were predictive for the development of Grade ≥2 (p = 0.001, p = 0.03) and Grade 3 (p = 0.05, p < 0.001) chronic urinary toxicity. On Cox multivariate analysis the development of acute toxicity was independently predictive for the development of both Grade ≥2 and Grade 3 chronic urinary toxicity. Conclusions Acute urinary toxicity and bladder wall dose–volume endpoints are strong predictors for the development of subsequent chronic urinary toxicity. Our recommendation is to attempt to limit the bladder wall V30 to <30 cm3 and the V82 to <7 cm3 when possible. If bladder wall information is not available, bladder solid V30 and V82 may be used. To identify factors predictive for chronic urinary toxicity secondary to high-dose adaptive three-dimensional conformal radiation. From 1999 to 2002, 331 consecutive patients with clinical Stage II–III prostate cancer were prospectively treated (median dose, 75.6 Gy). The bladder was contoured, and the bladder wall was defined as the outer 3 mm of the bladder solid volume. Toxicity was quantified according to the National Cancer Institute Common Toxicity Criteria 2.0. Median follow-up was 1.6 years. The 3-year rates of Grade ≥2 and Grade 3 chronic urinary toxicity were 17.0% and 3.6%, respectively. Prostate volume, confidence-limited patient-specific planning target volume, bladder wall volume, and acute urinary toxicity were all found to be accurate predictors for chronic urinary toxicity. The volume of bladder wall receiving ≥30 Gy (V30) and ≥82 Gy (V82), along with prostate volume, were all clinically useful predictors of Grade ≥2 and Grade 3 chronic urinary toxicity and chronic urinary retention. Both Grade ≥2 (p = 0.001) and Grade 3 (p = 0.03) acute urinary toxicity were predictive for the development of Grade ≥2 (p = 0.001, p = 0.03) and Grade 3 (p = 0.05, p < 0.001) chronic urinary toxicity. On Cox multivariate analysis the development of acute toxicity was independently predictive for the development of both Grade ≥2 and Grade 3 chronic urinary toxicity. Acute urinary toxicity and bladder wall dose–volume endpoints are strong predictors for the development of subsequent chronic urinary toxicity. Our recommendation is to attempt to limit the bladder wall V30 to <30 cm3 and the V82 to <7 cm3 when possible. If bladder wall information is not available, bladder solid V30 and V82 may be used." @default.
• W2017834862 created "2016-06-24" @default.
• W2017834862 creator A5006101201 @default.
• W2017834862 creator A5006151030 @default.
• W2017834862 creator A5016407136 @default.
• W2017834862 creator A5017328433 @default.
• W2017834862 creator A5017606947 @default.
• W2017834862 creator A5034586842 @default.
• W2017834862 creator A5059255743 @default.
• W2017834862 creator A5072574772 @default.
• W2017834862 creator A5075699837 @default.
• W2017834862 creator A5089368839 @default.
• W2017834862 date "2007-11-01" @default.
• W2017834862 modified "2023-09-27" @default.
• W2017834862 title "Predictors for Chronic Urinary Toxicity After the Treatment of Prostate Cancer With Adaptive Three-Dimensional Conformal Radiotherapy: Dose–Volume Analysis of a Phase II Dose-Escalation Study" @default.
• W2017834862 cites W1868732334 @default.
• W2017834862 cites W1977616639 @default.
• W2017834862 cites W1978906140 @default.
• W2017834862 cites W1979616411 @default.
• W2017834862 cites W1979914233 @default.
• W2017834862 cites W2009896026 @default.
• W2017834862 cites W2010126914 @default.
• W2017834862 cites W2023801183 @default.
• W2017834862 cites W2025027678 @default.
• W2017834862 cites W2030105102 @default.
• W2017834862 cites W2040501025 @default.
• W2017834862 cites W2050792510 @default.
• W2017834862 cites W2056504792 @default.
• W2017834862 cites W2056643793 @default.
• W2017834862 cites W2076755148 @default.
• W2017834862 cites W2091013692 @default.
• W2017834862 cites W2091073002 @default.
• W2017834862 cites W2097512974 @default.
• W2017834862 cites W2114214906 @default.
• W2017834862 cites W2128760486 @default.
• W2017834862 cites W2138538184 @default.
• W2017834862 cites W2149407830 @default.
• W2017834862 cites W2156107767 @default.
• W2017834862 cites W2163217542 @default.
• W2017834862 cites W2170080153 @default.
• W2017834862 cites W4249727657 @default.
• W2017834862 cites W4293241248 @default.
• W2017834862 doi "https://doi.org/10.1016/j.ijrobp.2007.04.076" @default.
• W2017834862 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17967304" @default.
• W2017834862 hasPublicationYear "2007" @default.
• W2017834862 type Work @default.
• W2017834862 sameAs 2017834862 @default.
• W2017834862 citedByCount "87" @default.
• W2017834862 countsByYear W20178348622012 @default.
• W2017834862 countsByYear W20178348622013 @default.
• W2017834862 countsByYear W20178348622014 @default.
• W2017834862 countsByYear W20178348622015 @default.
• W2017834862 countsByYear W20178348622016 @default.
• W2017834862 countsByYear W20178348622017 @default.
• W2017834862 countsByYear W20178348622018 @default.
• W2017834862 countsByYear W20178348622019 @default.
• W2017834862 countsByYear W20178348622020 @default.
• W2017834862 countsByYear W20178348622021 @default.
• W2017834862 countsByYear W20178348622023 @default.
• W2017834862 crossrefType "journal-article" @default.
• W2017834862 hasAuthorship W2017834862A5006101201 @default.
• W2017834862 hasAuthorship W2017834862A5006151030 @default.
• W2017834862 hasAuthorship W2017834862A5016407136 @default.
• W2017834862 hasAuthorship W2017834862A5017328433 @default.
• W2017834862 hasAuthorship W2017834862A5017606947 @default.
• W2017834862 hasAuthorship W2017834862A5034586842 @default.
• W2017834862 hasAuthorship W2017834862A5059255743 @default.
• W2017834862 hasAuthorship W2017834862A5072574772 @default.
• W2017834862 hasAuthorship W2017834862A5075699837 @default.
• W2017834862 hasAuthorship W2017834862A5089368839 @default.
• W2017834862 hasConcept C121608353 @default.
• W2017834862 hasConcept C126322002 @default.
• W2017834862 hasConcept C126894567 @default.
• W2017834862 hasConcept C143998085 @default.
• W2017834862 hasConcept C2776235491 @default.
• W2017834862 hasConcept C2779762690 @default.
• W2017834862 hasConcept C2780192828 @default.
• W2017834862 hasConcept C29730261 @default.
• W2017834862 hasConcept C53164099 @default.
• W2017834862 hasConcept C71924100 @default.
• W2017834862 hasConcept C77411442 @default.
• W2017834862 hasConceptScore W2017834862C121608353 @default.
• W2017834862 hasConceptScore W2017834862C126322002 @default.
• W2017834862 hasConceptScore W2017834862C126894567 @default.
• W2017834862 hasConceptScore W2017834862C143998085 @default.
• W2017834862 hasConceptScore W2017834862C2776235491 @default.
• W2017834862 hasConceptScore W2017834862C2779762690 @default.
• W2017834862 hasConceptScore W2017834862C2780192828 @default.
• W2017834862 hasConceptScore W2017834862C29730261 @default.
• W2017834862 hasConceptScore W2017834862C53164099 @default.
• W2017834862 hasConceptScore W2017834862C71924100 @default.
• W2017834862 hasConceptScore W2017834862C77411442 @default.
• W2017834862 hasIssue "4" @default.
• W2017834862 hasLocation W20178348621 @default.
• W2017834862 hasLocation W20178348622 @default.
• W2017834862 hasOpenAccess W2017834862 @default.
• W2017834862 hasPrimaryLocation W20178348621 @default.
• W2017834862 hasRelatedWork W1975326703 @default.

• next